Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

NCT00115635 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: docetaxel
DRUG: gemcitabine

Sponsor

Herlev Hospital

Collaborators

[object Object]
[object Object]